Inicio>>GS-443902 sodium

GS-443902 sodium

Catalog No.GC39386

El GS-443902 sÓdico (GS-441524 trifosfato trisÓdico) es un potente inhibidor de las polimerasas de ARN dependientes de ARN viral (RdRp) con IC50 de 1,1 μM, 5 μM para RSV RdRp y HCV RdRp, respectivamente.

Products are for research use only. Not for human use. We do not sell to patients.

GS-443902 sodium Chemical Structure

Cas No.: 1355050-21-3

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL Water)
2.375,00 $
Disponible
1mg
908,00 $
Disponible
5mg
1.808,00 $
Disponible
10mg
2.735,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

GS-443902 sodium (GS-441524 triphosphate sodium) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC50s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively. GS-443902 sodium is the active triphosphate metabolite of Remdesivir (GS-5734)[1][2].

[1]. Siegel D, et al. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. Med Chem. 2017 Mar 9;60(5):1648-1661. [2]. Cho A, et al. Synthesis and antiviral activity of a series of 1’-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2705-7. [3]. Warren TK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016 Mar 17;531(7594):381-5.

Reseñas

Review for GS-443902 sodium

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GS-443902 sodium

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.